{"generic":"Nedocromil Sodium","drugs":["Alocril","Nedocromil Sodium"],"mono":{"0":{"id":"393000-s-0","title":"Generic Names","mono":"Nedocromil Sodium"},"1":{"id":"393000-s-1","title":"Dosing and Indications","sub":{"0":{"id":"393000-s-1-4","title":"Adult Dosing","mono":"<ul><li>Tilade(R) inhaler has been voluntarily discontinued by the manufacturer. The discontinuation was due to multiple factors, including inability to find a qualified manufacturer for a chlorofluorocarbon propellant inhaler. Tilade(R) will be available through pharmacies and wholesalers until depletion of current supplies.<\/li><li><b>Allergic conjunctivitis:<\/b> 1 to 2 drops in each eye twice daily<\/li><\/ul>"},"1":{"id":"393000-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>Tilade(R) inhaler has been voluntarily discontinued by the manufacturer. The discontinuation was due to multiple factors, including inability to find a qualified manufacturer for a chlorofluorocarbon propellant inhaler. Tilade(R) will be available through pharmacies and wholesalers until depletion of current supplies.<\/li><li>OPHTHALMIC PREPARATION, under age 3, safety and effectiveness not established<\/li><li><b>Allergic conjunctivitis:<\/b> age 3 yr and older, 1 to 2 drops in each eye twice daily<\/li><\/ul>"},"3":{"id":"393000-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Tilade(R) inhaler has been voluntarily discontinued by the manufacturer. The discontinuation was due to multiple factors, including inability to find a qualified manufacturer for a chlorofluorocarbon propellant inhaler. Tilade(R) will be available through pharmacies and wholesalers until depletion of current supplies [1].<\/li><li>Allergic conjunctivitis<\/li><li>Asthma<\/li><\/ul>"}}},"3":{"id":"393000-s-3","title":"Contraindications\/Warnings","sub":{"0":{"id":"393000-s-3-9","title":"Contraindications","mono":"hypersensitivity to nedocromil sodium<br\/>"},"2":{"id":"393000-s-3-11","title":"Pregnancy Category","mono":"<ul><li>Nedocromil: B (FDA)<\/li><li>Nedocromil: B1 (AUS)<\/li><\/ul>"},"3":{"id":"393000-s-3-12","title":"Breast Feeding","mono":"Nedocromil: Micromedex: Infant risk cannot be ruled out.<br\/>"}}},"5":{"id":"393000-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Bad taste in mouth, Nausea, Vomiting<\/li><li><b>Neurologic:<\/b>Dizziness, Headache<\/li><li><b>Ophthalmic:<\/b>Burning sensation in eye, Conjunctivitis, Photophobia<\/li><li><b>Respiratory:<\/b>Cough, Nasal congestion, Pain in throat, Rhinitis<\/li><\/ul>"},"6":{"id":"393000-s-6","title":"Drug Name Info","sub":{"0":{"id":"393000-s-6-17","title":"US Trade Names","mono":"Alocril<br\/>"},"2":{"id":"393000-s-6-19","title":"Class","mono":"<ul><li>Antiasthma<\/li><li>Mast Cell Stabilizer<\/li><li>Ophthalmologic Agent<\/li><\/ul>"},"3":{"id":"393000-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"393000-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"393000-s-7","title":"Mechanism Of Action","mono":"Nedocromil sodium is an anti-inflammatory agent that blocks the release of mediators of hypersensitivity reactions from mast cells, eosinophils, neutrophils, macrophages, monocytes and platelets. The drug inhibits the release of histamine from mast cells and beta-glucuronidase from macrophages in bronchoalveolar cells. It does not exert any bronchodilating, antihistaminic, or corticosteroid effects.<br\/>"},"8":{"id":"393000-s-8","title":"Pharmacokinetics","sub":[{"id":"393000-s-8-23","title":"Absorption","mono":"<ul><li>Inhalational: time to peak concentration, 28 min<\/li><li>Inhalational, asthmatic adults: time to peak concentration, 5 min to 90 min<\/li><li>Bioavailability: (inhalational), 17%<\/li><li>Bioavailability: (oral), less than 2%<\/li><li>Bioavailability: (ophthalmic), less than 4%<\/li><\/ul>"},{"id":"393000-s-8-24","title":"Distribution","mono":"Protein binding: (inhalational), approximately 89% <br\/>"},{"id":"393000-s-8-25","title":"Metabolism","mono":"Not metabolized <br\/>"},{"id":"393000-s-8-26","title":"Excretion","mono":"<ul><li>Fecal: (IV, healthy adult male), 36% unchanged<\/li><li>Fecal: (ophthalmic), 30% unchanged<\/li><li>Renal: (inhalational, asthmatic adult), approximately 5% unchanged<\/li><li>Renal: (inhalational, healthy adult), 12% unchanged<\/li><li>Renal: (IV, healthy adult), approximately 70% unchanged<\/li><li>Renal: (IV, healthy adult male), 64% unchanged<\/li><li>Renal: (ophthalmic), 70% unchanged<\/li><\/ul>"},{"id":"393000-s-8-27","title":"Elimination Half Life","mono":"<ul><li>Inhalational: (healthy adult), 3.3 h<\/li><li>Inhalational: (asthmatic adult), 1.5 h<\/li><\/ul>"}]},"9":{"id":"393000-s-9","title":"Administration","mono":"<b>General Information<\/b><br\/>regular use throughout the period of exposure is recommended, even when symptoms are absent <br\/>"},"10":{"id":"393000-s-10","title":"Monitoring","mono":"<ul><li>proper technique of inhalation<\/li><li>(inhalation) reduction in asthma symptoms<\/li><li>(ophthalmic) symptomatic improvement<\/li><li>(inhalation) pulmonary function tests<\/li><\/ul>"},"11":{"id":"393000-s-11","title":"How Supplied","mono":"<b>Alocril<\/b><br\/>Ophthalmic Solution: 2 %<br\/>"},"13":{"id":"393000-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient that the inhaled formulation is not indicated for acute asthma attacks.<\/li><li>Inhaled preparation may cause a bad taste in mouth, nausea, vomiting, dizziness, headache, conjunctivitis, cough, nasal congestion, throat pain, or rhinitis. The ophthalmic formulation may also cause a burning sensation in the eye.<\/li><li>Tell patients using ophthalmic form to not wear contact lenses during drug therapy.<\/li><li>Instruct patient on proper administration technique, depending on formulation.<\/li><\/ul>"}}}